FibroGen, Inc (NASDAQ:FGEN) insider K Peony Yu sold 37,500 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.58, for a total value of $1,896,750.00. Following the completion of the sale, the insider now directly owns 236,507 shares of the company’s stock, valued at $11,962,524.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

K Peony Yu also recently made the following trade(s):

  • On Tuesday, August 1st, K Peony Yu sold 10,000 shares of FibroGen stock. The shares were sold at an average price of $33.48, for a total value of $334,800.00.
  • On Monday, July 10th, K Peony Yu sold 5,000 shares of FibroGen stock. The shares were sold at an average price of $32.98, for a total value of $164,900.00.
  • On Wednesday, June 14th, K Peony Yu sold 3,721 shares of FibroGen stock. The shares were sold at an average price of $28.95, for a total value of $107,722.95.

Shares of FibroGen, Inc (FGEN) traded down 5.84% on Thursday, hitting $41.10. The company had a trading volume of 1,226,276 shares. The company’s market capitalization is $2.93 billion. The firm has a 50-day moving average price of $34.46 and a 200 day moving average price of $28.07. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $51.70.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.01. The firm had revenue of $29 million during the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. Equities analysts expect that FibroGen, Inc will post ($1.82) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “FibroGen, Inc (FGEN) Insider K Peony Yu Sells 37,500 Shares” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/fibrogen-inc-fgen-insider-k-peony-yu-sells-37500-shares/1470879.html.

Several equities research analysts have recently weighed in on the company. William Blair reissued an “outperform” rating on shares of FibroGen in a research report on Wednesday. Leerink Swann reissued an “outperform” rating and issued a $82.00 price objective (up from $52.00) on shares of FibroGen in a research report on Tuesday. Citigroup Inc. increased their price objective on FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday. Jefferies Group LLC reissued a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research report on Tuesday. Finally, Stifel Nicolaus upped their target price on FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $60.17.

A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the period. Principal Financial Group Inc. increased its stake in FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after buying an additional 504 shares during the period. Rothschild Asset Management Inc. increased its stake in FibroGen by 0.5% in the first quarter. Rothschild Asset Management Inc. now owns 186,005 shares of the biopharmaceutical company’s stock valued at $4,585,000 after buying an additional 959 shares during the period. OppenheimerFunds Inc. increased its stake in FibroGen by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 356,236 shares of the biopharmaceutical company’s stock valued at $8,781,000 after buying an additional 1,066 shares during the period. Finally, Algert Global LLC increased its stake in FibroGen by 6.4% in the first quarter. Algert Global LLC now owns 24,322 shares of the biopharmaceutical company’s stock valued at $600,000 after buying an additional 1,466 shares during the period. Institutional investors and hedge funds own 43.45% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.